Practical expert insights for riding the COVID-19 wave and emerging stronger
The COVID-19 pandemic has seen unprecedented pressure on pharma’s supply chain. From public stockpiling and basic materials sourcing to supplier management and locked-down logistics channels, all aspects of the supply chain have been stretched at a time when the uninterrupted flow of medicines is most critical.
The speed of the COVID-19 pandemic has exposed fragility in some aspects of pharma’s supply chain structure. But this is an opportunity as well as a challenge and provides powerful lessons which, if implemented, will radically improve overall supply chain efficiency and resilience in the long-term.
Experts provide unique insights and guidance
That is why this new report is critical reading. By harnessing multidisciplinary expertise, the report maps COVID-19-related problems and solutions throughout the entire supply chain. Uniquely, the report goes beyond the technical aspects of the supply chain to provide insights into the psychology of those behaviours that could disrupt the supply chain further, such as stockpiling or organisational complacency.
Key questions examined include…
- Do you understand pandemic-driven human behaviour and how to ease the pressure it places on the supply chain?
- Decreased output due to sick leave in production is a high risk, so what steps can pharma take to nurture resilient employees in critical roles?
- How can companies better illuminate supply chain blind spots through improved monitoring of their Tier 2/3 suppliers?
- Is it time to prioritise cooperation over competition by sharing inventory data, and what tools can facilitate this?
- A lack of geo-diversity and reliance on single sources and countries is one of pharma’s biggest risk factors: what can be done?
- Are you stuck in a hybrid model between the traditional and smart supply chain? If so, how can you accelerate the digital transformation and enter supply chain 4.0?
- What can we draw from the UK government’s phased approach to COVID-19 and the US government’s war on COVID-19 that will help create resilient supply chains?
Drawing on experts worldwide to contribute specialist knowledge and insights
To capture the widest experience and insights, this report is based on primary research with 35 relevant experts, including:
➢Amgen works collaboratively with suppliers via supply chain mapping
➢Biogen manages natural disasters via supply chain mapping
➢The NHS harnesses the power of data sharing to fight COVID-19
➢MediLedger’s potential value during COVID-19
➢The Inventory Management and Tracking System for the US Strategic National Stockpile
➢ DHL supply chain risk resilience platform and COVID-19
➢The Australian government guide pharmacists through COVID-19
➢Johnson & Johnson’s ethical framework for decision-making during COVID-19
➢ The UK Influenza Pandemic Plan
➢ The US Supply Chain Stabilization Task Force
➢The Strategic National Stockpile partnership-driven approach
➢Johnson & Johnson harness technology and data for an “advanced manufacturing ecosystem”
➢Unravelling the toilet roll stockpiling phenomenon – lessons for pharma
➢ Introducing Supply Chain 4.0
"This is such an important and timely body of research. I strongly recommend picking up the report but only if you are seeking practical, action oriented advice."
The Risk Project, LLC
"This report is very useful as it explains every aspect of supply chain functions and offers the views of multidisciplinary expertise from different pharma groups."
Supply Chain Management, Sun Pharmaceuticals
"This is an outstanding in-depth report into an under-reported impact of the pandemic that could impact us all—everyone concerned with the supply of medicines should read it."
Editor, The Pharma Letter
"This is amazing work, and we were thrilled to be part of it and contribute to and support your effort."
"That's an amazing report! Well done, I didn't realise you were working on something so extensive."
"Awesome work. You're a terrific writer and researcher."
World Employee Experience Institute
"The report is great – lots of content, depth, and recommendations. You really can see how much work you've put into it."
Pharma and Healthcare Editor
About the Author
Dr Nicola Davies is a highly-respected and experienced writer and commentator on the global pharmaceutical and life sciences industry. She has an extensive and detailed understanding of the important clinical and commercial issues that are shaping and influencing pharma’s development. In this report, she has harnessed the inputs of leading supply chain and behavioural science experts and applied her deep industry knowledge to present actionable insights for reforming and improving critical supply chain capabilities.